News

Results Found (492)
October 25, 2007
A new peptide communication factor enabling bacteria to ‘talk to each...

The research, patented by Yissum,  could lead to a new class of antibiotics

October 17, 2007
Yissum spin-off Conjugate Develops New and Improved Sugar-based Drugs...
October 15, 2007
Yissum spin-off Collplant looks to TASE IPO

The company first plans to raise several million dollars in a private placement.

October 14, 2007
Goldman Sachs investing $100m in Yissum's spin off Mobileye

Investment bank Goldman Sachs is investing $100 million in the Israeli company Mobileye. This reflects a valuation of $600 million. 

 

August 16, 2007
An international research with Hebrew University Researchers found that the...

August 16, 2007
A new Consortium in the Water Cleantech field initiated by Yissum and the...

Hebrew University and the technology transfer company Yissum announced on Wednesday that formation of a new consortium to develop water technology, the first such project in Israel.

The consortium has been awarded an operational budget for three...

August 14, 2007
Teva buys Asthma treatment rights from Yissum

The treatment was found in testing to have eliminated four different types of allergic diseases in mice.

August 8, 2007
Yissum and Protalix BioTherapeutics Sign Agreement to License...

Protalix BioTherapeutics, Inc. , today announced it has signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel, and the Boyce Thompson Institute for Plant...

August 1, 2007
Hebrew U.'s Yissum teams with Neocrine Biosciences

Neocrine Biosciences Inc. will develop valnoctamide, which has potential for treating neurological and psychiatric disorders discovered at Hebrew University.

July 26, 2007
Virtual eternal life is not science fiction but rather a technological...

Prof. Naftali Tishby dreams of the day when we will be able transfer a copy of our souls onto the computer before our death so that the soul will continue to think, feel, and answer our grandchildren's questions long after our bodies...

July 25, 2007
Yissum spin-off Novagali Pharma files prospectus for Euronext IPO

The French-Israeli eye drug maker uses technology developed by the Hebrew University of Jerusalem.

July 3, 2007
Merck reinventing itself- an interview with Dr. Strulovici, Merck's VP for...

Merck shopping for new technologies for the improvement of drug development